CureGate Español

KRAS G12C lung cancer clinical trials in Los Angeles

This page lists recruiting research studies near Los Angeles for people with non-small cell lung cancer that has a KRAS G12C change, and for the families helping them.

Each study decides who can join. CureGate’s free service helps people understand which studies may be worth asking an oncologist about.

Start the free quick check →Four questions. No records needed. Call Aria (855) 606-1679CureGate’s AI assistant, in English or Spanish.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.

CureGate partner site

These studies are open at a CureGate partner site. CureGate works with this site, which is why they are shown first. Being listed here is not a recommendation, and only the study team can confirm who can join.

  • KANDLELIT-004 · Phase 3

    For KRAS G12C non-small cell lung cancer that has spread or cannot be removed with surgery, not yet treated for advanced disease, with PD-L1 of 50% or higher. Compares calderasib (a KRAS G12C pill) plus pembrolizumab with pembrolizumab plus placebo.

    Where: Beverly Hills Cancer Center (Clinical Research Advisors), Beverly Hills, CA

    View on ClinicalTrials.gov (NCT06345729)
  • KANDLELIT-007 · Phase 3

    For KRAS G12C nonsquamous non-small cell lung cancer that has spread or cannot be removed with surgery, not yet treated for advanced disease. Compares calderasib plus pembrolizumab given under the skin with pembrolizumab plus chemotherapy.

    Where: Beverly Hills Cancer Center (Clinical Research Advisors), Beverly Hills, CA

    View on ClinicalTrials.gov (NCT07190248)
See if these studies may fit → Call Aria (855) 606-1679

Start from the biomarker result, if there is one

Pick what fits best. “I don’t know” is a perfectly good answer.

KRAS G12C Another KRAS change (such as G12D or G12V) EGFR A different result (ALK, ROS1, MET, RET, HER2 or other) Tested, but not sure of the result Not tested, or I don’t know

What is KRAS G12C?

KRAS is a gene that helps control how cells grow. In some lung cancers the gene has a change (a mutation). G12C names one specific change, at position 12 of the KRAS protein.

Doctors find it with biomarker testing (also called molecular, genomic or next-generation sequencing testing) on a tumor sample or a blood sample. KRAS G12C is one of the more common changes found in non-small cell lung cancer.

There are FDA-approved medicines that target KRAS G12C, and many research studies are testing newer approaches, including studies for people who have already received one of those medicines.

Not sure about biomarker results? That is common.

Many people do not know whether biomarker testing was done, or what it found. You do not need to know to get started.

Places to look: a report from a lab such as Foundation Medicine, Tempus, Caris or Guardant; the pathology section of the patient portal; or ask the oncology office, “Was comprehensive biomarker testing done, and can I get a copy of the report?”

If you choose to share records with CureGate, CureGate’s research team can help find the biomarker results and explain what they mean for study options.

Start the quick check without a result → Call Aria (855) 606-1679

27 recruiting KRAS-related lung cancer studies near Los Angeles

Data from ClinicalTrials.gov as of November 3, 2026. Grouped by what each study’s eligibility criteria ask for. Study status can change at any time; titles are shown as registered. Confirm details with each study team.

Studies that include people who have not yet had treatment for advanced disease

  1. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    Phase
    3
    Recruiting in
    Fullerton, Long Beach
    Last updated

  2. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  3. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    Phase
    2
    Recruiting in
    Los Angeles, Orange
    Last updated

  4. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Phase
    3
    Recruiting in
    Irvine, Los Angeles, Newport Beach, Orange
    Last updated

Studies for people who already received a KRAS G12C medicine

  1. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    Phase
    1/2
    Recruiting in
    Orange
    Last updated

Other KRAS G12C studies

  1. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  2. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    Phase
    2/3
    Recruiting in
    Anaheim, Cerritos, Long Beach, Los Alamitos
    Last updated

  3. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Phase
    1
    Recruiting in
    Santa Monica
    Last updated

  4. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  5. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    Phase
    3
    Recruiting in
    Los Angeles
    Last updated

  6. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    Phase
    3
    Recruiting in
    Los Angeles, Orange
    Last updated

  7. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    Phase
    1
    Recruiting in
    Santa Monica
    Last updated

  8. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  9. Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

    Phase
    1
    Recruiting in
    Duarte, Irvine
    Last updated

Studies open to other KRAS or RAS changes (for example G12D or G12V)

  1. A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

    Phase
    3
    Recruiting in
    Glendale, Los Angeles
    Last updated

  2. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

  4. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  5. A Study of ASP3082 in Adults With Advanced Solid Tumors

    Phase
    1
    Recruiting in
    Duarte, Santa Monica
    Last updated

  6. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    Phase
    1
    Recruiting in
    Duarte, Los Angeles
    Last updated

  7. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    Phase
    3
    Recruiting in
    Long Beach
    Last updated

  8. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase
    1
    Recruiting in
    Duarte, Los Angeles, Newport Beach
    Last updated

  9. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  10. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    Phase
    1/2
    Recruiting in
    Orange
    Last updated

  11. A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  12. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Phase
    1/2
    Recruiting in
    Orange, Santa Monica
    Last updated

  13. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    Phase
    1
    Recruiting in
    Westwood, Los Angeles
    Last updated

How CureGate helps

Answer four quick questions to see how many recruiting studies may fit. No records are needed.

Aria, CureGate’s AI assistant, can call back to help with the next steps. Aria may ask whether biomarker testing was done; “I don’t know” is fine.

CureGate’s research team reviews everything before any study site is contacted, and nothing is shared without permission.

Start the free quick check →Four questions. No records needed. Call Aria (855) 606-1679CureGate’s AI assistant, in English or Spanish.

Support and education

Patient groups such as the LUNGevity Foundation, GO2 for Lung Cancer and the American Cancer Society offer free education about biomarker testing and lung cancer.

Frequently asked questions

Do I need to know the exact KRAS result to ask about a study?

No. Many people are not sure of their results. You can still use CureGate’s quick check, and if you choose to share records later, CureGate’s research team can help find the biomarker report.

What if the test found a KRAS change that is not G12C?

Some studies are open to other KRAS or RAS changes, such as G12D or G12V. They are listed separately on this page when ClinicalTrials.gov shows them recruiting near Los Angeles.

Are there studies for people who already took sotorasib or adagrasib?

Some studies are designed for people whose cancer grew after a KRAS G12C medicine. When ClinicalTrials.gov lists them near Los Angeles, they appear in their own group above. Only the study team can confirm whether someone can join.

What is biomarker testing?

Biomarker testing looks for gene changes or proteins in a tumor or blood sample. Results are often in a report from a lab such as Foundation Medicine, Tempus, Caris or Guardant, or in the pathology section of the medical record. An oncologist can explain which tests were done.

What does CureGate do with the answer I pick on this page?

It stays in your browser for this visit so the quick check can start in the right place. It is not used for advertising, and nothing is shared with a study site unless you say so.

Is CureGate running these studies?

No. CureGate is an independent matching service. The studies are run by their sponsors and research sites, and a listing on this page is not a recommendation of any study.

Does CureGate’s help cost anything?

No. CureGate’s service is free for patients and families. Ask each study team what the study covers.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.